Tate & Lyle (TATE) Trading Update summary
Event summary combining transcript, slides, and related documents.
Trading Update summary
17 Dec, 2025Operating performance and financials
Achieved solid volume and EBITDA growth in Q3, with Food & Beverage Solutions volume up 4% across all regions.
Group revenue declined 4% due to pass-through of input cost deflation, but Sucralose revenue rose 19% from strong customer demand.
Sucralose delivered another record quarter, with some order pull-forward expected to unwind in Q4.
Productivity savings advanced, supporting progress toward a US$150 million five-year target.
Year-to-date and Q3 EBITDA growth remained positive.
Financial results and balance sheet
Group revenue for the quarter was £423m, up 14% including CP Kelco; Food & Beverage Solutions revenue was £296m, down 4%.
Sucralose revenue reached £41m, up 19%; Primary Products Europe revenue declined 24% to £20m.
Cash generation remained strong, with cash conversion aligned with long-term goals.
Completed a £215m share buyback and raised US$300m and €275m in private placement to refinance CP Kelco acquisition.
Tax rate expected at 22%-23%, with stable financing following an oversubscribed US private placement.
Strategic developments and integration
Completed acquisition of CP Kelco, accelerating growth strategy and expanding specialty portfolio.
CP Kelco performed in line with expectations, showing strong volume and revenue growth, especially in pectin.
Integration progressing well; full operational merger set for April 2025, with $50m cost synergy target by FY27.
Customers are responding positively to the expanded solutions and innovation pipeline.
Expanded global reach, now serving customers in over 120 countries with more than 5,000 employees.
Latest events from Tate & Lyle
- Q3 revenue rose 15% reported, but pro forma revenue fell 2%; outlook remains unchanged.TATE
Q3 2026 TU2 Mar 2026 - $1.8B deal creates a global specialty food leader with strong synergies and growth prospects.TATE
Business Combination (Q&A)3 Feb 2026 - A $1.8B deal creates a global specialty food leader, targeting strong cost and revenue synergies.TATE
Business Combination3 Feb 2026 - EBITDA up 6% and margin expands as specialty strategy advances with CP Kelco and Primient sale.TATE
H1 202516 Jan 2026 - EBITDA up 6%, cash flow strong, and strategic transformation completed.TATE
H1 2025 (Q&A)16 Jan 2026 - H1 revenue and EBITDA to decline as integration synergies are offset by softer demand.TATE
H1 2026 TU17 Dec 2025 - Transformed into a high-margin specialty leader, targeting accelerated growth and innovation.TATE
CMD 202521 Nov 2025 - Specialty focus and CP Kelco integration drive EBITDA and cash flow growth amid tariff risks.TATE
H2 202519 Nov 2025 - Revenue and EBITDA declined 3% and 6%, but CP Kelco synergies and growth actions advance.TATE
H1 202613 Nov 2025